United Therapeutics Corporation
1040 Spring Street
Silver Spring,
MD 20910
United States - Map
Phone: 301-608-9292
Fax: 301-608-9291
Website: http://www.unither.com
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Ch14.18 MAb, an antibody that is under Phase III clinical trails for the treatment of neuroblastoma; Beraprost 314d, which is under Phase II clinical trails for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trail for the treatment of metastatic brain cancer. Further, the company is involved in the early pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and PLacental eXpanded cells for the treatment of PAH; glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. Key Statistics
| |
| United Therapeutics Corporation’s ISS Governance QuickScore as of May 1, 2013 is 8. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 10; Compensation: 7. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Ms. Martine A. Rothblatt Ph.D., J.D., MBA,
58
Founder, Chairman and Chief Exec. Officer | 1.97M | 0.00 | Dr. Roger A. Jeffs Ph.D.,
51
Pres, Chief Operating Officer and Director | 1.40M | 71.00K | Mr. John M. Ferrari ,
58
Chief Financial Officer, Principal Accounting Officer and Treasurer | 859.00K | 0.00 | Mr. Paul A. Mahon J.D.,
49
Exec. VP of Strategic Planning, Gen. Counsel and Corp. Sec. | 1.11M | 0.00 | Jay A. Watson Pharm.D.,
Sr. VP of Strategic Operations & Logistics | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
1.26(1.86%) May 24, 4:00PM EDT|After Hours
:
66.35 0.00 (0.00%) May 24, 4:05PM EDT